Overview
Lobbying Costs
17,500€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.75 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Pentaferte Italia Srl
EU Transparency Register
806455437398-80 First registered on 19 Feb 2020
Goals / Remit
Production of syringes and medical devices
Pentaferte is an Italian company which operates in European and extra-European markets. The industrial activity of manufacturing medical devices is the “DNA” of this Italian company which, over the years, has been able to follow and anticipate market developments, in terms of quality standards and demand for safety products in the medical world.
The production site in Campli, in the province of Teramo, is among the most important and complete facilities in Europe. The commercial and administrative headquarters in Ferrara manage the timely and efficient distribution of Penta products in all markets, through a network of distributors or directly to public or private hospitals.
The production site in Campli, in the province of Teramo, is among the most important and complete facilities in Europe. The commercial and administrative headquarters in Ferrara manage the timely and efficient distribution of Penta products in all markets, through a network of distributors or directly to public or private hospitals.
A Company Quality System is in place and is currently certified by TÜV Italia in compliance with UNI EN ISO 9001:2008 and UNI EN ISO 13485:2012.
The long-term presence in hospitals and chemist’s shops throughout Europe as well as the CE certification of its products, issued by TÜV Sud Product Service Munich, ensure a high quality standard. Anyone wishing to find out more about
Pentaferte’s production and culture is welcome to visit the production site in Campli (TE)The site includes offices, services, warehouses, production and accommodation.
The working days are Monday to Friday, over three shifts (24 hours a day) for the production and control personnel and one daily shift for the office personnel. The total area covered by the site is over 20,000 m².
Research follows the constantly evolving market needs and demands for innovation from end users.Main EU files targeted
Activities deemed to influence, directly and indirectly the European Policies regarding:
Health Secor
Manufacturing Standard
Quality COntrol
Consumer's Protection
Environmental Sustainabilities
Pentaferte is also officially registered to the United Nations Global Compact for divulgatingits 10 CSR (Corporate Social Responsability ) Principles and is a Member of the UNGM United Nations Global Marketpalce
Pentaferte is actively lobbying at EU Level for theamelioration of quality in the world of medical devices has the critical aspect of innovation and quality and, on the basis of these pillars, the objective of providing users with the solution to their problems, in a safe, reliable way takes shape.
Investing in research means improving our medical culture and offering it to those who, by using Pentaferte products, can increase the level of wellbeing and safety of patients and ill people, i.e EU Consumers..Address
Head Office
Viale Piane Nocella, 23 - 64012 Campli (TE) - Italy
Campli (TE) 64012
ITALY -
People
Total lobbyists declared
1
Employment time Lobbyists 75% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Affiliation with Pentaferte France, French company
Since 1997 Pentaferte has been present on the French market. Pentaferte France, with its management and distribution headquarters in Paris, is involved in the distribution and marketing of various European brands dedicated to the hospital and home healthcare fields. The French staff follow the market and customer requirements directly, constantly collaborating with the Italian office to develop new products and new solutions for the end-customers.
The direct presence on the market and the peculiarity of the distributed products make Pentaferte France the company expressing the greatest demand for research and development in our industrial group. Over the years, Pentaferte France has experienced a steady growth and growing results, both in terms of expansion over the territory and in terms of development of new skills. Among the latter, the acquisition of Segap, a historic French company that was the first to address the issue of safe enteral feeding, in compliance with European standard EN 1615.Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
17,500€
Other financial info
Work force 2019: 90 units
Budget Pentaferte 2019: € 10.818.198
Official Participant UNGC ( United Nations Global compact) ID 128951.
Registration UNMG (United Nations Global Marketplace) N. 529345 -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Organization of specialized sector-related events and seminars as well as direct and indirect contacts with EU MPs and National MPs on the harmonization of the following key issues:
1) Health Secor
2) Manufacturing Standard
3) Quality COntrol
4) Consumer's Protection
5) Environmental SustainabilitiesOther activities
Qualitiy policy
Due to the importance of the sector in which it operates, Pentaferte is aware that the quality of its devices is the fundamental basis for customer safety. To this end, it establishes, maintains and improves its quality management system in order to meet customer requirements, while respecting the principles of UNI EN ISO 9001:2008 and ISO 13485:2003 and in accordance with the legislation regulating the medical sector.
This is summarised in the COMPANY MISSION as set out below:
All PENTAFERTE personnel work every day, in a dedicated, flexible and dynamic manner, to offer safe devices useful for safeguarding human health.
The Quality Manual, of which this document is an integral part, give a detailed description of all actions and checks that are carried out in order to achieve the objectives that the company sets itself in a satisfactory manner. In particular, the achievement of these objectives requires the implementation of strategies aimed at ensuring:
improved customer service, paying the utmost attention to present and future needs and aiming to exceed customer expectations;
the development of human resources, promoting the unity of purpose and direction by company managers, who are responsible for creating and maintaining an internal environment which is motivated and fully involved in the pursuit of the quality objectives;
improved product quality, planning and implementing interventions that can help reduce the percentage of non-conforming products. Focus on core business and special ranges with high marginality;
the continuous improvement of overall performance, through the identification, analysis and systematic management of all those processes that are interconnected to achieve a specific objective;
the retention of existing customers and the achievement of a dominant position in Europe in the sale of devices from the enteral range.
The General Management has defined this quality policy and ensures that it is understood, implemented and sustained at all levels of the organisation. All employees are required to implement it and include it in their activities. The General Management also undertakes to adapt its human, economic/financial and infrastructure resources to the requirements that will come about during management.
In order to give practical effect to these commitments, once a year, as part of the relevant activities, the General Management establishes specific objectives for the company management, related to the responsibilities and contributions of each member in relation to the company’s strategic goals. The data resulting from the application of the Quality Management System is analysed by the General Management during the annual review, in order to verify the implementation and effectiveness and to promote continuous improvement
Meetings
Meetings
None declared